Onco Wiki / Biomarker

HER2-Status (fester Tumor — Magen-/GEJ/CRC-Wertung)

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

Biomarker-Fakten

Verwendet von

Therapeutische Relevanz

• BMA-HER2-AMP-CHOLANGIO - HER2-verstärkte Gallenwegskrebs (~5-15% insgesamt; angereichert mit Gallenblase + Extrahepat...
• BMA-HER2-AMP-CRC - HER2-verstärkter metastasierter Kolorektalkarzinom (~3-5% in der RAS/BRAF-WT-Population): Tucatinib...
• BMA-HER2-AMP-ESOPHAGEAL - HER2-positives Esophageal/GEJ Adenokarzinom nach Magenkriterien: Trastuzumab + che...
• BMA-HER2-AMP-GASTRIC - HER2-positives Magen-/GEJ-Adenokarzinom (~15-20%): Trastuzumab + Chemotherapie ist...

Algorithmen

• ALGO-ESOPH-METASTATIC-1L - ALGO-ESOPH-METASTATIC-1L

Biomarker

• BIO-CLDN18-2 - Claudin-18.2 Ausdruck (CLDN18.2)
• BIO-ESTROGEN-RECEPTOR - Östrogenrezeptor (ER)
• BIO-FGFR2B-IHC - FGFR2b Proteinexpression durch IHC (membranöse Färbung)
• BIO-HER2-LOW - HER2-niedrig (Brust — IHC 1+ ODER IHC 2+ ISH-negativ)
• BIO-HER2-ULTRALOW - HER2-ultralow (Brust — IHC > 0 < 1+; schwache/unvollständige Membranfärbung ≤ 10 %)

Erkrankung

• DIS-CHOLANGIOCARCINOMA - Cholangiokarzinom (ZNS-Krebs)
• DIS-SALIVARY - Speicheldrüsenkarzinom

Kapitel des Handbuchs

• HB-BREAST-HER2-POS-MET-1L - HER2+ metastasierter Brustkrebs:
• HB-BREAST-HR-POS-HER2-NEG-1L - HR+/HER2- metastasierter Brustkrebs:

Anwendungsgebiet

• IND-BREAST-BRCA-MET-TALAZOPARIB - IND-BREAST-BRCA-MET-TALAZOPARIB
• IND-BREAST-BRCA-POS-MET-PARPI - IND-BREAST-BRCA-POS-MET-PARPI
• IND-BREAST-HER2-LOW-2L-DATO-DXD - IND-BREAST-HER2-LOW-2L-DATO-DXD
• IND-BREAST-HER2-POS-3L-TUCATINIB - IND-BREAST-HER2-POS-3L-TUCATINIB
• IND-BREAST-HER2-POS-EARLY-NEOADJUVANT - IND-BREAST-HER2-POS-EARLY-NEOADJUVANT
• IND-BREAST-HER2-POS-MAINT-TRAST - IND-BREAST-HER2-POS-MAINT-TRAST
• IND-BREAST-HER2-POS-MET-1L-THP - IND-BREAST-HER2-POS-MET-1L-THP
• IND-BREAST-HER2-POS-MET-2L-TDXD - IND-BREAST-HER2-POS-MET-2L-TDXD
• IND-BREAST-HR-POS-1L-INAVOLISIB - IND-BREAST-HR-POS-1L-INAVOLISIB
• IND-BREAST-HR-POS-2L-AKT-CAPIVASERTIB - IND-BREAST-HR-POS-2L-AKT-CAPIVASERTIB
• IND-BREAST-HR-POS-2L-DATO-DXD - IND-BREAST-HR-POS-2L-DATO-DXD
• IND-BREAST-HR-POS-2L-ESR1-ELACESTRANT - IND-BREAST-HR-POS-2L-ESR1-ELACESTRANT
• IND-BREAST-HR-POS-2L-FUL-EVEROLIMUS - IND-BREAST-HR-POS-2L-FUL-EVEROLIMUS
• IND-BREAST-HR-POS-2L-PIK3CA-ALPELISIB - IND-BREAST-HR-POS-2L-PIK3CA-ALPELISIB
• IND-BREAST-HR-POS-2L-T-DXD-HER2-LOW - IND-BREAST-HR-POS-2L-T-DXD-HER2-LOW
• IND-BREAST-HR-POS-3L-POST-CDK46I-POST-AKT - IND-BREAST-HR-POS-3L-POST-CDK46I-POST-AKT
• IND-BREAST-HR-POS-EARLY-ADJ-CDK46I - IND-BREAST-HR-POS-EARLY-ADJ-CDK46I
• IND-BREAST-HR-POS-EARLY-ADJ-RIBOCICLIB - IND-BREAST-HR-POS-EARLY-ADJ-RIBOCICLIB
• IND-BREAST-HR-POS-MAINT-CDK46I - IND-BREAST-HR-POS-MAINT-CDK46I
• IND-BREAST-HR-POS-MET-1L-CDKI - IND-BREAST-HR-POS-MET-1L-CDKI
• IND-BREAST-TNBC-2L-BRCA-OLAPARIB - IND-BREAST-TNBC-2L-BRCA-OLAPARIB
• IND-BREAST-TNBC-2L-BRCA-TALAZOPARIB - IND-BREAST-TNBC-2L-BRCA-TALAZOPARIB
• IND-BREAST-TNBC-2L-DATO-DXD - IND-BREAST-TNBC-2L-DATO-DXD
• IND-BREAST-TNBC-2L-SACITUZUMAB - IND-BREAST-TNBC-2L-SACITUZUMAB
• IND-BREAST-TNBC-2L-T-DXD-HER2-LOW - IND-BREAST-TNBC-2L-T-DXD-HER2-LOW
• IND-BREAST-TNBC-3L-POST-SACI-POST-T-DXD - IND-BREAST-TNBC-3L-POST-SACI-POST-T-DXD
• IND-BREAST-TNBC-EARLY-NEOADJUVANT - IND-BREAST-TNBC-EARLY-NEOADJUVANT
• IND-CHOLANGIO-2L-HER2-ZANIDATAMAB - IND-CHOLANGIO-2L-HER2-ZANIDATAMAB
• IND-CRC-METASTATIC-2L-HER2-AMP-T-DXD - IND-CRC-METASTATIC-2L-HER2-AMP-T-DXD
• IND-CRC-METASTATIC-2L-HER2-AMP-TUCATINIB - IND-CRC-METASTATIC-2L-HER2-AMP-TUCATINIB
• IND-ESOPH-METASTATIC-1L-HER2-TRASTUZUMAB-CHEMO - IND-ESOPH-METASTATIC-1L-HER2-TRASTUZUMAB-CHEMO
• IND-ESOPH-METASTATIC-2L-HER2-POSITIVE-T-DXD - IND-ESOPH-METASTATIC-2L-HER2-POSITIVE-T-DXD
• IND-ESOPH-OLIGOMET-SYSTEMIC-PLUS-LOCAL - IND-ESOPH-OLIGOMET-SYSTEMIC-PLUS-LOCAL
• IND-GASTRIC-METASTATIC-1L-CLDN18-2-ZOLBETUXIMAB - IND-GASTRIC-METASTATIC-1L-CLDN18-2-ZOLBETUXIMAB
• IND-GASTRIC-METASTATIC-1L-FGFR2B-BEMARITUZUMAB - IND-GASTRIC-METASTATIC-1L-FGFR2B-BEMARITUZUMAB
• IND-GASTRIC-METASTATIC-1L-HER2-TOGA - IND-GASTRIC-METASTATIC-1L-HER2-TOGA
• IND-GASTRIC-METASTATIC-1L-PDL1-CHEMO-ICI - IND-GASTRIC-METASTATIC-1L-PDL1-CHEMO-ICI
• IND-GASTRIC-METASTATIC-2L-HER2-TDXD - IND-GASTRIC-METASTATIC-2L-HER2-TDXD
• IND-GASTRIC-METASTATIC-2L-RAMUCIRUMAB-PACLITAXEL - IND-GASTRIC-METASTATIC-2L-RAMUCIRUMAB-PACLITAXEL
• IND-GASTRIC-OLIGOMET-SYSTEMIC-PLUS-LOCAL - IND-GASTRIC-OLIGOMET-SYSTEMIC-PLUS-LOCAL
• ... 2 weitere

Fragebogen

• QUEST-BREAST-1L-STUB - Invasiver Brustkrebs — erste Zeile
• QUEST-CRC-1L-STUB - Kolorektales Karzinom — erste Zeile
• QUEST-GASTRIC-1L-STUB - Magen- und gastroösophageale Kreuzung Adenokarzinom — erste Zeile
• QUEST-NSCLC-1L-STUB - Non-small cell lung cancer — first line

Warnhinweis

• RF-BREAST-HIGH-RISK-BIOLOGY - Germlin- oder somatische BRCA1/2-Mutation, PIK3CA-Mutation, ESR1-Mutation, HER2-Amplifikation,...
• RF-CHOLANGIOCARCINOMA-HIGH-RISK-BIOLOGY - Einsetzbare molekulare Veränderung des Cholangiokarzinoms — FGFR2 Fusion / Neuordnung, IDH...
• RF-CRC-HER2-AMP-ACTIONABLE - HER2-Verstärkung bei metastasierendem Kolorektalkarzinom — IHC 3+ ODER (IHC 2+ UND ISH verstärkt,...
• RF-SALIVARY-HIGH-RISK-BIOLOGY - Speicheldrüsen-Karzinom mit einführbaren molekularen Treiber: ETV6-NTRK3 Fusion (Mamma...

Prüfungen

• TEST-HER2-IHC-FISH - HER2 IHC + Reflex FISH auf Tumor